KPRX — KIORA PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1372514 ·
Last close
$2.63
Market Cap
$11.64M
52W High
$2.95
52W Low
$1.76
ADV30
15,810
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,124,357 | -2,079,010 | 23,776,090 | 7,076,533 | 6,919,401 |
| Mar 2026 | 0 | — | -2,502,768 | -2,417,984 | 21,227,089 | 10,955,359 | 7,292,528 |
| Dec 2025 | 0 | — | -2,630,193 | -6,516,521 | 24,253,300 | 8,696,570 | 8,126,764 |
| Sep 2025 | 0 | — | -2,515,470 | 26,806 | 29,863,454 | 5,508,899 | 7,452,712 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,418,309
Investing CF
$17,154,845
Financing CF
$264,813
CapEx
$-83,612
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.63
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-156,635,260
Inventory
—
Receivables
$3,451,176
ST Investments
$2,916,701
EBIT TTM
$-12,544,949
Pretax Income TTM
$-12,465,314
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,459,247 | -10,835,154 | 24,253,300 | 8,126,764 | 16,126,536 | -9,961,176 |
| Dec 2024 | 16,000,000 | 5,580,819 | 3,594,733 | 36,484,484 | 10,724,708 | 25,759,776 | 8,559,115 |
| Dec 2023 | 0 | -8,690,183 | -12,513,896 | 13,711,870 | 7,602,216 | 6,109,654 | -9,556,951 |
| Dec 2022 | 0 | -11,726,918 | -13,583,610 | 18,678,259 | 7,270,659 | 11,407,600 | -10,428,133 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-11,212,612
OpCashFlow TTM
$0
Assets (Latest)
$24,253,300
Forward EPS
$-2.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ASBP | Aspire Biopharma Holdings, Inc. | $11.67M | $8.32 | — |
| MBRX | Moleculin Biotech, Inc. | $11.73M | $0.60 | — |
| PHIO | Phio Pharmaceuticals Corp. | $11.73M | $1.01 | — |
| SCNX | Scienture Holdings, Inc. | $11.37M | $0.28 | — |
| CALC | CalciMedica, Inc. | $11.95M | $1.75 | — |
News headlines (Yahoo Finance, 1h cache)
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
2026-08-19 11:00 · Yahoo
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
2026-07-02 11:00 · Yahoo
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-08 11:00 · Yahoo
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
2026-04-07 11:00 · Yahoo
Kiora Pharmaceuticals Announces Management Team Changes
2026-04-02 20:30 · Yahoo
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
2026-04-14 11:00 · Yahoo
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
2026-09-08 11:00 · Yahoo
SS Innovations International (SSII) Appoints Sarah Romano as Chief Financial Officer
2026-07-15 18:25 · Yahoo
SS Innovations names Sarah Romano as CFO
2026-07-15 05:03 · Yahoo
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
2026-06-18 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.